Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia

Cancer Cell

Volumn 22, Issue 2, 2012, Pages 153-166

  Roberts, Kathryn G ^a   Morin, Ryan D ^b   Zhang, Jinghui ^a   Hirst, Martin ^b   Zhao, Yongjun ^b   Su, Xiaoping ^a   Chen, Shann Ching ^a   Payne Turner, Debbie ^a   Churchman, Michelle L ^a   Harvey, Richard C ^c   Chen, Xiang ^a   Kasap, Corynn ^d   Yan, Chunhua ^e   Becksfort, Jared ^a   Finney, Richard P ^e   Teachey, David T ^g   Maude, Shannon L ^g   Tse, Kane ^b   Moore, Richard ^b   Jones, Steven ^b   Mungall, Karen ^b   Birol, Inanc ^b   Edmonson, Michael N ^e   Hu, Ying ^e   Buetow, Kenneth E ^e   Chen, I Ming ^c   Carroll, William L ^h   Wei, Lei ^a   Ma, Jing ^a   Kleppe, Maria ⁱ   Levine, Ross L ⁱ   Garcia Manero, Guillermo ^j   Larsen, Eric ^k   Shah, Neil P ^d   Devidas, Meenakshi ^l   Reaman, Gregory ^m   Smith, Malcolm ^f   Paugh, Steven W ^a   Evans, William E ^a   Grupp, Stephan A ^g   Jeha, Sima ^a   Pui, Ching Hon ^a   Gerhard, Daniela S ^f   Downing, James R ^a   Willman, Cheryl L ^c   Loh, Mignon ^d   Hunger, Stephen P ⁿ   Marra, Marco A ^b,o   Mullighan, Charles G ^a   more..

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c UNIVERSITY OF NEW MEXICO   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

^g CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^h NEW YORK UNIVERSITY   (United States)

ⁱ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^j UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^k Maine Children's Cancer Program Scarborough   (United States)

^l UNIVERSITY OF FLORIDA   (United States)

^m CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

ⁿ UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^o UNIVERSITY OF BRITISH COLUMBIA   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CYTOKINE RECEPTOR; DASATINIB; FLT3 LIGAND; IMATINIB; INTERLEUKIN 7 RECEPTOR; JANUS KINASE 2; MESSENGER RNA; PROTEIN TYROSINE KINASE INHIBITOR; RUXOLITINIB; TRANSCRIPTOME;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ARTICLE; CANCER PATIENT; CANCER THERAPY; CHROMOSOME REARRANGEMENT; CLINICAL ARTICLE; FEMALE; GENE DELETION; GENE EXPRESSION PROFILING; GENE MUTATION; GENE REARRANGEMENT; GENE SEQUENCE; GENOME; HIGH RISK PATIENT; HUMAN; MALE; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RNA SEQUENCE; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84865118132     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2012.06.005     Document Type: Article

References (62)

1. Apperley J.F., Gardembas M., Melo J.V., Russell-Jones R., Bain B.J., Baxter E.J., Chase A., Chessells J.M., Colombat M., Dearden C.E., et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N. Engl. J. Med. 2002, 347:481-487.
2. Armstrong S.A., Kung A.L., Mabon M.E., Silverman L.B., Stam R.W., Den Boer M.L., Pieters R., Kersey J.H., Sallan S.E., Fletcher J.A., et al. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell 2003, 3:173-183.
3. Bernad R., van der Velde H., Fornerod M., Pickersgill H. Nup358/RanBP2 attaches to the nuclear pore complex via association with Nup88 and Nup214/CAN and plays a supporting role in CRM1-mediated nuclear protein export. Mol. Cell. Biol. 2004, 24:2373-2384.
4. Bowman W.P., Larsen E.L., Devidas M., Linda S.B., Blach L., Carroll A.J., Carroll W.L., Pullen D.J., Shuster J., Willman C.L., et al. Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: results of Children's Oncology Group trial P9906. Pediatr. Blood Cancer 2011, 57:569-577.
5. Carroll M., Tomasson M.H., Barker G.F., Golub T.R., Gilliland D.G. The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways. Proc. Natl. Acad. Sci. USA 1996, 93:14845-14850.
6. Chapiro E., Russell L., Lainey E., Kaltenbach S., Ragu C., Della-Valle V., Hanssens K., Macintyre E.A., Radford-Weiss I., Delabesse E., et al. Activating mutation in the TSLPR gene in B-cell precursor lymphoblastic leukemia. Leukemia 2010, 24:642-645.
7. Cirmena G., Aliano S., Fugazza G., Bruzzone R., Garuti A., Bocciardi R., Bacigalupo A., Ravazzolo R., Ballestrero A., Sessarego M. A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11) in a patient with acute myeloid leukemia. Cancer Genet. Cytogenet. 2008, 183:105-108.
8. Cross N.C., Reiter A. Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders. Acta Haematol. 2008, 119:199-206.
9. De Braekeleer E., Douet-Guilbert N., Rowe D., Bown N., Morel F., Berthou C., Férec C., De Braekeleer M. ABL1 fusion genes in hematological malignancies: a review. Eur. J. Haematol. 2011, 86:361-371.
10. De Keersmaecker K., Rocnik J.L., Bernad R., Lee B.H., Leeman D., Gielen O., Verachtert H., Folens C., Munck S., Marynen P., et al. Kinase activation and transformation by NUP214-ABL1 is dependent on the context of the nuclear pore. Mol. Cell 2008, 31:134-142.
11. Deenik W., Beverloo H.B., van der Poel-van de Luytgaarde S.C., Wattel M.M., van Esser J.W., Valk P.J., Cornelissen J.J. Rapid complete cytogenetic remission after upfront dasatinib monotherapy in a patient with a NUP214-ABL1-positive T-cell acute lymphoblastic leukemia. Leukemia 2009, 23:627-629.
12. Den Boer M.L., van Slegtenhorst M., De Menezes R.X., Cheok M.H., Buijs-Gladdines J.G., Peters S.T., Van Zutven L.J., Beverloo H.B., Van der Spek P.J., Escherich G., et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol. 2009, 10:125-134.
13. Downing J.R., Wilson R.K., Zhang J., Mardis E.R., Pui C.H., Ding L., Ley T.J., Evans W.E. The pediatric cancer genome project. Nat. Genet. 2012, 44:619-622.
14. Edmonson M.N., Zhang J., Yan C., Finney R.P., Meerzaman D.M., Buetow K.H. Bambino: a variant detector and alignment viewer for next-generation sequencing data in the SAM/BAM format. Bioinformatics 2011, 27:865-866.
15. Golub T.R., Barker G.F., Lovett M., Gilliland D.G. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 1994, 77:307-316.
16. Graux C., Cools J., Melotte C., Quentmeier H., Ferrando A., Levine R., Vermeesch J.R., Stul M., Dutta B., Boeckx N., et al. Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat. Genet. 2004, 36:1084-1089.
17. Griesinger F., Hennig H., Hillmer F., Podleschny M., Steffens R., Pies A., Wörmann B., Haase D., Bohlander S.K. A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia. Genes Chromosomes Cancer 2005, 44:329-333.
18. Hagman J., Lukin K. Transcription factors drive B cell development. Curr. Opin. Immunol. 2006, 18:127-134.
19. Hagman J., Gutch M.J., Lin H., Grosschedl R. EBF contains a novel zinc coordination motif and multiple dimerization and transcriptional activation domains. EMBO J. 1995, 14:2907-2916.
20. Harvey R.C., Mullighan C.G., Chen I.M., Wharton W., Mikhail F.M., Carroll A.J., Kang H., Liu W., Dobbin K.K., Smith M.A., et al. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood 2010, 115:5312-5321.
21. Harvey R.C., Mullighan C.G., Wang X., Dobbin K.K., Davidson G.S., Bedrick E.J., Chen I.M., Atlas S.R., Kang H., Ar K., et al. Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. Blood 2010, 116:4874-4884.
22. Hertzberg L., Vendramini E., Ganmore I., Cazzaniga G., Schmitz M., Chalker J., Shiloh R., Iacobucci I., Shochat C., Zeligson S., et al. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood 2010, 115:1006-1017.
23. Iacobucci I., Storlazzi C.T., Cilloni D., Lonetti A., Ottaviani E., Soverini S., Astolfi A., Chiaretti S., Vitale A., Messa F., et al. Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP). Blood 2009, 114:2159-2167.
24. Kotecha N., Flores N.J., Irish J.M., Simonds E.F., Sakai D.S., Archambeault S., Diaz-Flores E., Coram M., Shannon K.M., Nolan G.P., Loh M.L. Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates. Cancer Cell 2008, 14:335-343.
25. Kuiper R.P., Schoenmakers E.F., van Reijmersdal S.V., Hehir-Kwa J.Y., van Kessel A.G., van Leeuwen F.N., Hoogerbrugge P.M. High-resolution genomic profiling of childhood ALL reveals novel recurrent genetic lesions affecting pathways involved in lymphocyte differentiation and cell cycle progression. Leukemia 2007, 21:1258-1266.
26. Marth, G. (2010) MOSAIK assembler. Available from http://bioinformatics.bc.edu/marthlab/Mosaik.
27. Martinelli G., Iacobucci I., Storlazzi C.T., Vignetti M., Paoloni F., Cilloni D., Soverini S., Vitale A., Chiaretti S., Cimino G., et al. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. J. Clin. Oncol. 2009, 27:5202-5207.
28. McPherson A., Hormozdiari F., Zayed A., Giuliany R., Ha G., Sun M.G., Griffith M., Heravi Moussavi A., Senz J., Melnyk N., et al. deFuse: an algorithm for gene fusion discovery in tumor RNA-Seq data. PLoS Comput. Biol. 2011, 7:e1001138.
29. Melo J.V. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 1996, 88:2375-2384.
30. Mizuki M., Fenski R., Halfter H., Matsumura I., Schmidt R., Müller C., Grüning W., Kratz-Albers K., Serve S., Steur C., et al. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood 2000, 96:3907-3914.
31. Morin R.D., Johnson N.A., Severson T.M., Mungall A.J., An J., Goya R., Paul J.E., Boyle M., Woolcock B.W., Kuchenbauer F., et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat. Genet. 2010, 42:181-185.
32. Mullighan C.G., Goorha S., Radtke I., Miller C.B., Coustan-Smith E., Dalton J.D., Girtman K., Mathew S., Ma J., Pounds S.B., et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007, 446:758-764.
33. Mullighan C.G., Miller C.B., Radtke I., Phillips L.A., Dalton J., Ma J., White D., Hughes T.P., Le Beau M.M., Pui C.H., et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 2008, 453:110-114.
34. Mullighan C.G., Collins-Underwood J.R., Phillips L.A., Loudin M.G., Liu W., Zhang J., Ma J., Coustan-Smith E., Harvey R.C., Willman C.L., et al. Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat. Genet. 2009, 41:1243-1246.
35. Mullighan C.G., Su X., Zhang J., Radtke I., Phillips L.A., Miller C.B., Ma J., Liu W., Cheng C., Schulman B.A., et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N. Engl. J. Med. 2009, 360:470-480. Children's Oncology Group.
36. Mullighan C.G., Zhang J., Harvey R.C., Collins-Underwood J.R., Schulman B.A., Phillips L.A., Tasian S.K., Loh M.L., Su X., Liu W., et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc. Natl. Acad. Sci. USA 2009, 106:9414-9418.
37. Nebral K., Denk D., Attarbaschi A., König M., Mann G., Haas O.A., Strehl S. Incidence and diversity of PAX5 fusion genes in childhood acute lymphoblastic leukemia. Leukemia 2009, 23:134-143.
38. Oh S.T., Simonds E.F., Jones C., Hale M.B., Goltsev Y., Gibbs K.D., Merker J.D., Zehnder J.L., Nolan G.P., Gotlib J. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood 2010, 116:988-992.
39. Paietta E., Ferrando A.A., Neuberg D., Bennett J.M., Racevskis J., Lazarus H., Dewald G., Rowe J.M., Wiernik P.H., Tallman M.S., Look A.T. Activating FLT3 mutations in CD117/KIT(+) T-cell acute lymphoblastic leukemias. Blood 2004, 104:558-560.
40. Pardanani A., Lasho T., Finke C., Oh S.T., Gotlib J., Tefferi A. LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations. Leukemia 2010, 24:1713-1718.
41. Pui C.H., Robison L.L., Look A.T. Acute lymphoblastic leukaemia. Lancet 2008, 371:1030-1043.
42. Pui C.H., Campana D., Pei D., Bowman W.P., Sandlund J.T., Kaste S.C., Ribeiro R.C., Rubnitz J.E., Raimondi S.C., Onciu M., et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N. Engl. J. Med. 2009, 360:2730-2741.
43. Quintás-Cardama A., Tong W., Manshouri T., Vega F., Lennon P.A., Cools J., Gilliland D.G., Lee F., Cortes J., Kantarjian H., Garcia-Manero G. Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies. Leukemia 2008, 22:1117-1124.
44. Robertson G., Schein J., Chiu R., Corbett R., Field M., Jackman S.D., Mungall K., Lee S., Okada H.M., Qian J.Q., et al. De novo assembly and analysis of RNA-seq data. Nat. Methods 2010, 7:909-912.
45. Röttgers S., Gombert M., Teigler-Schlegel A., Busch K., Gamerdinger U., Slany R., Harbott J., Borkhardt A. ALK fusion genes in children with atypical myeloproliferative leukemia. Leukemia 2010, 24:1197-1200.
46. Russell L.J., Capasso M., Vater I., Akasaka T., Bernard O.A., Calasanz M.J., Chandrasekaran T., Chapiro E., Gesk S., Griffiths M., et al. Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood 2009, 114:2688-2698.
47. Russell L.J., De Castro D.G., Griffiths M., Telford N., Bernard O., Panzer-Grümayer R., Heidenreich O., Moorman A.V., Harrison C.J. A novel translocation, t(14;19)(q32;p13), involving IGH@ and the cytokine receptor for erythropoietin. Leukemia 2009, 23:614-617.
48. Schnittger S., Schoch C., Dugas M., Kern W., Staib P., Wuchter C., Löffler H., Sauerland C.M., Serve H., Büchner T., et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002, 100:59-66.
49. Schultz K.R., Bowman W.P., Aledo A., Slayton W.B., Sather H., Devidas M., Wang C., Davies S.M., Gaynon P.S., Trigg M., et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J. Clin. Oncol. 2009, 27:5175-5181.
50. Shah S.P., Morin R.D., Khattra J., Prentice L., Pugh T., Burleigh A., Delaney A., Gelmon K., Guliany R., Senz J., et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 2009, 461:809-813.
51. Shochat C., Tal N., Bandapalli O.R., Palmi C., Ganmore I., te Kronnie G., Cario G., Cazzaniga G., Kulozik A.E., Stanulla M., et al. Gain-of-function mutations in interleukin-7 receptor-α (IL7R) in childhood acute lymphoblastic leukemias. J. Exp. Med. 2011, 208:901-908.
52. Smyth G.K. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 2004, 2004, 3:Article3.
53. Tasian S.K., Doral M.Y., Borowitz M.J., Wood B.L., Chen I.-M., Harvey R.C., Gastier-Foster J.M., Willman C.L., Hunger S.P., Mullighan C.G., Loh M.L. Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia. Blood 2012, 10.1182/blood-2011-12-389932.
54. Teachey D.T., Obzut D.A., Cooperman J., Fang J., Carroll M., Choi J.K., Houghton P.J., Brown V.I., Grupp S.A. The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood 2006, 107:1149-1155.
55. Tibshirani R., Hastie T., Narasimhan B., Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc. Natl. Acad. Sci. USA 2002, 99:6567-6572.
56. Tong W., Zhang J., Lodish H.F. Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways. Blood 2005, 105:4604-4612.
57. Wang J., Mullighan C.G., Easton J., Roberts S., Heatley S.L., Ma J., Rusch M.C., Chen K., Harris C.C., Ding L., et al. CREST maps somatic structural variation in cancer genomes with base-pair resolution. Nat. Methods 2011, 8:652-654.
58. Williams R.T., Roussel M.F., Sherr C.J. Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia. Proc. Natl. Acad. Sci. USA 2006, 103:6688-6693.
59. Yoda A., Yoda Y., Chiaretti S., Bar-Natan M., Mani K., Rodig S.J., West N., Xiao Y., Brown J.R., Mitsiades C., et al. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc. Natl. Acad. Sci. USA 2010, 107:252-257.
60. Zenatti P.P., Ribeiro D., Li W., Zuurbier L., Silva M.C., Paganin M., Tritapoe J., Hixon J.A., Silveira A.B., Cardoso B.A., et al. Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. Nat. Genet. 2011, 43:932-939.
61. Zhang J., Mullighan C.G., Harvey R.C., Wu G., Chen X., Edmonson M., Buetow K.H., Carroll W.L., Chen I.M., Devidas M., et al. Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 2011, 118:3080-3087.
62. Zhang J., Ding L., Holmfeldt L., Wu G., Heatley S.L., Payne-Turner D., Easton J., Chen X., Wang J., Rusch M., et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012, 481:157-163.